Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-3512676 in Cutaneous T-Cell Lymphoma
NCT00043420Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2003
- Primary completion
- Mar 2007
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
01
Overview
Phase 2, randomised, open-label trial of agatolimod in mycosis fungoides (MF) (8 arms), sponsored by Pfizer. Primary endpoints: Safety: Adverse events, vital signs, clinical and laboratory parameters, physical exams, and ECGs at 24 weeks and Overall Tumor Response Rate assessed by Composite Assessment of Index Lesion Disease Severity (CA) at 24 weeks. Started Jan 2003; status: completed.
02
Drugs
agatolimod
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT00043420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00043420.